These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30587971)

  • 1. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
    Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
    Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
    Li D; Hu C; Yang J; Liao Y; Chen Y; Fu SZ; Wu JB
    Int J Nanomedicine; 2020; 15():10045-10058. PubMed ID: 33328733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
    Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
    Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
    Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN
    Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
    DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
    Vysyaraju NR; Paul M; Ch S; Ghosh B; Biswas S
    J Drug Target; 2022 Dec; 30(10):1088-1105. PubMed ID: 35723068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
    Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
    Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
    Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
    Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
    Parsels LA; Engelke CG; Parsels J; Flanagan SA; Zhang Q; Tanska D; Wahl DR; Canman CE; Lawrence TS; Morgan MA
    Mol Cancer Ther; 2021 Feb; 20(2):263-273. PubMed ID: 33268569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
    Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
    Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
    Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
    Lesueur P; Lequesne J; Grellard JM; Dugué A; Coquan E; Brachet PE; Geffrelot J; Kao W; Emery E; Berro DH; Castera L; Goardon N; Lacroix J; Lange M; Capel A; Leconte A; Andre B; Léger A; Lelaidier A; Clarisse B; Stefan D
    BMC Cancer; 2019 Mar; 19(1):198. PubMed ID: 30832617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.